{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T08:39:35Z","timestamp":1784623175785,"version":"3.55.0"},"reference-count":29,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2014,12,9]],"date-time":"2014-12-09T00:00:00Z","timestamp":1418083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2015,4,15]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Neurogenic orthostatic hypotension (nOH) results from failure of norepinephrine responses to postural change to maintain standing systolic blood pressure (s\u2010SBP). Droxidopa is an oral prodrug of norepinephrine. Study nOH306 enrolled patients with Parkinson's disease (PD) and symptomatic nOH. Subjects underwent up to 2 weeks of double\u2010blind titration of droxidopa or placebo, followed by 8 weeks of double\u2010blind maintenance treatment (100\u2010600 mg thrice\u2010daily). For the initial 51 subjects (study nOH306A, previously reported), the primary efficacy measure, Orthostatic Hypotension Questionnaire (OHQ) composite score, did not demonstrate significant change versus placebo at maintenance week 8. For the subsequent 171 subjects (study nOH306B, reported here), the primary efficacy measure was change versus placebo on item 1 (\u201cdizziness, lightheadedness, feeling faint, or feeling like you might black out\u201d) of the Orthostatic Hypotension Symptom Assessment (OHSA) subsection of the OHQ at maintenance week 1. At week 1, mean (standard deviation) improvement on OHSA item 1 was 2.3 (2.95) for droxidopa versus 1.3 (3.16) for placebo (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.018). In addition, mean increase in s\u2010SBP at week 1 was 6.4 (18.85) for droxidopa versus 0.7 (20.18) mmHg for placebo (nominal\n                    <jats:italic>P<\/jats:italic>\n                    value: 0.032). Differences in change in OHSA item 1 scores from baseline to maintenance weeks 2, 4, and 8 were not statistically significant. Adverse\u2010event (AE) incidence was similar across groups, but 12.4% of droxidopa and 6.1% of placebo subjects withdrew because of AEs. The most common AEs on droxidopa (vs. placebo) were headache (13.5% vs. 7.3%) and dizziness (10.1% vs. 4.9%). Study nOH306B demonstrated subjective (OHSA item 1) and objective (s\u2010SBP) evidence of short\u2010term droxidopa efficacy (vs. placebo) for symptomatic nOH in PD. \u00a9 2014 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.\n                  <\/jats:p>","DOI":"10.1002\/mds.26086","type":"journal-article","created":{"date-parts":[[2014,12,9]],"date-time":"2014-12-09T12:37:31Z","timestamp":1418128651000},"page":"646-654","source":"Crossref","is-referenced-by-count":137,"title":["Droxidopa for the\n                    <scp>S<\/scp>\n                    hort\u2010\n                    <scp>T<\/scp>\n                    erm\n                    <scp>T<\/scp>\n                    reatment of\n                    <scp>S<\/scp>\n                    ymptomatic\n                    <scp>N<\/scp>\n                    eurogenic\n                    <scp>O<\/scp>\n                    rthostatic\n                    <scp>H<\/scp>\n                    ypotension in\n                    <scp>P<\/scp>\n                    arkinson's\n                    <scp>D<\/scp>\n                    isease (n\n                    <scp>OH<\/scp>\n                    306\n                    <scp>B<\/scp>\n                    )"],"prefix":"10.1002","volume":"30","author":[{"given":"Robert A.","family":"Hauser","sequence":"first","affiliation":[{"name":"University of South Florida Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Isaacson","sequence":"additional","affiliation":[{"name":"Parkinson's Disease and Movement Disorders Center of Boca Raton Boca Raton Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome P.","family":"Lisk","sequence":"additional","affiliation":[{"name":"Southern California Movement Disorder Specialists, Inc. Pasadena California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Arthur","family":"Hewitt","sequence":"additional","affiliation":[{"name":"Lundbeck NA Ltd. Deerfield Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerry","family":"Rowse","sequence":"additional","affiliation":[{"name":"Lundbeck NA Ltd. Deerfield Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,12,9]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp074189"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10286-011-0119-5"},{"key":"e_1_2_8_4_1","first-page":"1","article-title":"Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa","volume":"10","author":"Isaacson SH","year":"2014","journal-title":"Vasc Health Risk Manag"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2011.05.020"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2003.029413"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.63.5.584"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/01376517-200008000-00006"},{"key":"e_1_2_8_9_1","first-page":"163","article-title":"Falls in Parkinson's disease. Causes and impact on patients' quality of life","volume":"20","author":"Michalowska M","year":"2005","journal-title":"Funct Neurol"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20324"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198908000-00006"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)91317-1"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.9.2151"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02298955"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000083721.49847.D7"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000615"},{"key":"e_1_2_8_17_1","article-title":"Randomized\u2010withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa","author":"Biaggioni I","year":"2014","journal-title":"Hypertension"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10286-011-0146-2"},{"key":"e_1_2_8_19_1","unstructured":"MathiasCJ LowPA FreemanR HewittLA KaufmannH.Integrated efficacy analysis of droxidopa in 2 double\u2010blind placebo\u2010controlled phase 3 studies in patients with neurogenic orthostatic hypotension. Poster presented at the Movement Disorder Society's 16th Annual International Congress of Parkinson's Disease and Movement Disorders (MDS) 17\u201021 June 2012 Dublin Ireland. Poster 1296."},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-130259"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22340"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/26.5.353"},{"issue":"4","key":"e_1_2_8_23_1","first-page":"1","article-title":"A report of the Kellogg international working group on the prevention of falls in the elderly. The prevention of falls in later life","volume":"34","author":"Gibson MJ","year":"1987","journal-title":"Danish Med Bull"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2007.05.009"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10286-004-0229-4"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2003.11.003"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.spinee.2009.05.010"},{"issue":"1","key":"e_1_2_8_28_1","first-page":"S158","article-title":"Exercise for falls prevention in Parkinson's disease: a randomized controlled trial [abstract]","volume":"28","author":"Canning CG","year":"2013","journal-title":"Mov Disord"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000081216.11623.C3"},{"key":"e_1_2_8_30_1","unstructured":"U.S. Food and Drug Administration.Northera (droxidopa) capsules label. Available at:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/203202lbl.pdf. Accessed 26 July2014."}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.26086","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.26086","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mds.26086","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.26086","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:57:56Z","timestamp":1760957876000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.26086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,9]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,4,15]]}},"alternative-id":["10.1002\/mds.26086"],"URL":"https:\/\/doi.org\/10.1002\/mds.26086","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725270353.793502802","asserted-by":"object"}]},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,9]]}}}